Wegovy Pill Now Available Nationwide at Lower Prices
The first GLP-1 weight loss pill just hit pharmacy shelves across America—and it costs less than the injection. But if you're on Medi-Cal, there's some bad news coming.
The Wegovy Pill Is Finally Here
After months of anticipation, you can now get Wegovy in pill form at pharmacies across the country. Novo Nordisk announced this week that their once-daily oral semaglutide is broadly available nationwide—making it the first and only GLP-1 pill approved specifically for weight loss.
So what kind of results are we talking about? In clinical trials, people lost an average of about 14% of their body weight. Those who stuck with it through the full study saw closer to 17%. That's solid, though slightly less than what the injectable version delivers. For a lot of folks, skipping the needle might be worth that tradeoff.
Let's Talk Price
Here's the thing: the pill is actually cheaper than the injection. Cash-pay patients are looking at around $150 per month for the starter dose, scaling up to about $300 monthly for the highest dose. Compare that to the injectable Wegovy, which runs over $1,000 without insurance, and you can see why Novo Nordisk thinks this could open doors for more people.
The lower price also helps address those frustrating supply shortages that have plagued injectable semaglutide. More options means less scrambling to find your medication in stock.
Medicare and Medicaid Coverage Could Expand
In genuinely good news, CMS just unveiled something called the BALANCE Model. It's a voluntary program that lets Medicare Part D plans and state Medicaid agencies cover GLP-1 medications for weight management—not just diabetes.
The federal government will negotiate directly with Novo Nordisk and Eli Lilly (makers of Zepbound and Mounjaro) for lower net prices. There's also talk of standardized coverage terms and out-of-pocket limits. A separate Medicare GLP-1 demonstration program is slated for 2026.
Whether this actually translates to affordable coverage for you depends on whether your specific plan participates. But it's a step in the right direction.
California's Medi-Cal Is Going the Opposite Direction
Now for the frustrating part. If you're on Medi-Cal in California, coverage for weight-loss medications is about to get worse, not better.
Starting January 1, 2026, Wegovy, Zepbound, and Saxenda will be dropped from Medi-Cal's covered drug list entirely for weight loss. Ozempic, Rybelsus, and Mounjaro will still be covered—but only if you have a type 2 diabetes diagnosis. Obesity alone won't qualify.
This affects millions of Californians and highlights just how uneven GLP-1 access remains across the country. One state expands, another contracts. It's a patchwork system that leaves a lot of people stuck.
The Bottom Line
The Wegovy pill launching at lower prices is genuinely helpful news—especially if needles have been your dealbreaker or if you've struggled to find the injectable in stock. The CMS coverage expansion could eventually help millions more afford these medications through Medicare and Medicaid.
But "could" and "eventually" are doing a lot of work there. If you're in California on Medi-Cal, you've got until the end of 2025 to figure out your next steps. And for everyone else, insurance coverage remains the biggest wildcard in whether any of this pricing actually matters to your wallet.
